Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Amgen beats Street

AMGN reported second quarter adjusted EPS of $0.62, beating the Street's $0.59 estimate by $0.03 and up 27%

Read the full 181 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE